Axon price target raised to $237 from $200 at Credit Suisse

Credit Suisse analyst Sami Badri raised the firm’s price target on Axon to $237 from $200 and keeps an Outperform rating on the shares. The firm notes the company ended 2022 on a high note, posting revenue/Adjusted EBITDA of $336.1M/$65.9M, well above its estimates of $308.8M/$52.8M, driven by all around segment beats except for TASER Products, which came in below consensus but beat Credit Suisse’s estimates.